ARBS STUDIES’ EFFECTIVENESS AND SAFETY IN DECREASING BLOOD PRESSURE WITH NO SIGNIFICANT CHANGES IN OTHER CLINICAL AND BIOCHEMICAL PARAMETERS

Main Article Content

Dr. Jainish Kamlesh Kumar Modi
Dr. Nirav Rasiklal Patel
Dr. Alpesh Vadher

Keywords

.

Abstract

This study is for evaluation of efficacy and safety of ARBs in stage 1 Hypertensive patients (JNC 8).

Abstract 18 | PDF Downloads 13

References

1. Joint National Committee. The Seventh and eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
2. A Harrison’s Principles of Internal Medicine. 18 th edition, 2012
3. Mark C Houston: Dew in rights and approaches to reduce end organ damage in treatment of hypertension : subsets of hypertension approach, American heart journal, May 1992, vol.123.
4. A API Textbook of Medicine,9 th edition.
5. De Gasparo, M.; Catt, K.J.; Inagami, T.; Wright, J.W.; Unger, Th.(2000),"International Union of Pharmacology. XIII. The Angiotensin II Receptors",Pharmacoligical Reviews 52 (3): 415–472, PMID 10977869
6. Hunyady, L.; Ji, H.; Jagadeesh, G.; Zhang, M.; Gáborik, Z.; Mihalik, B. et al. et al.(1998), "Dependence of AT1 Angiotensin Receptor Function on Adjacent Asparagine Residues in the Seventh Transmembrane Helix", Molecular Pharmacology 54 (2): 427–434, PMID 9687585
7. Dihn, D.T.; Frauman, A.G.; Johnston, C.I.; Fabiani, M.E. (2001), "Angiotensin receptors: distribution, signalling and function", Clinical Science 100 (5):481–492,doi:10.1042/CS20000263, PMID 11294688
8. Matsubara, H. (1998), "Pathophysiological Role of Angiotensin II Type 2
9. Receptor in Cardiovascular and Renal Diseases", Circulation Research, Journal of the American Heart Association 83 (12):1182–1191, doi:10.1161/01.RES.83.12.1182,PMID 985193
10. Vinson, G.P.; Ho, M.M.; Puddefoot, J. R. (1995), "The distribution of angiotensin II type 1 receptors, and the tissue renin-angiotensin systems", Molecular MedicineToday 1 (1): 35–39, doi:10.1016/1357-4310(95)80018-2, PMID 9415136
11. Aulakh GK, Sodhi RK, Singh M; Sodhi; Singh (August 2007), "An update on non-peptide angiotensin receptor antagonists and related RAAS modulators", Life Sci. 81 (8): 615–39, doi:10.1016/j.lfs.2007.06.007,PMID 17692338
12. Goodman & Gilman‘s The Pharmacological Basis of Therapeutics 11th ed. (Renin
13. and Angiotensin; Jackson E.K., 789-821) Editors; Brunton L.L., Lazo J.S., Parker K.L. New York McGraw Hill 2006. ISBN 0-07-142280-3
14. . Levy, B.I. (2005), "How to Explain the Differences Between Renin Angiotensin System Modulators",American Journal of Hypertension 18 (9 Pt 2):134 1,doi:10.1016/j.amjhyper.2005.05.005,PMID 16125050
15. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2000.
16. Fasce and Wageman et al study: study of efficacy of losartan on hypertension. 199, 178: 150 - 160.
17. Levy D. The role of systolic blood pressure in determining risk for cardiovascular disease. J Hypertens. 1999;17(suppl 1):S15-S18.
18. . Lacourice et al study: Role of telmisartan on stage 1 hypertensive patients; 2000; 14: 150-200.
19. Liau et al study: efficacy of losartan and olmesartan on systolic and diastolic hypertension, 1998; 20:100-150.